Foghorn Therapeutics Inc.

Foghorn is a clinical stage, precision therapeutics biotechnology company focused on treating serious diseases by correcting abnormal gene expression. The company achieves this by selectively targeting the chromatin regulatory system, which is involved in approximately 50 percent of all cancers and has potential applications in immunology and inflammation. Foghorn utilizes its proprietary Gene Traffic Control® platform to understand how the chromatin regulatory system interacts, enabling the identification and validation of drug targets within this system. The company is currently working on more than seven programs, with one clinical-stage drug candidate in Phase 1 development. Foghorn has discovered selective chemical matter for oncology targets including SMARCA2 (BRM), CBP, EP300, and ARID1B, along with other undisclosed targets. The company employs a small molecule modality agnostic approach, including protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors. As part of a collaboration with Eli Lilly and Company, Lilly initiated a Phase 1 dose escalation trial for FHD-909 (LY4050784), a selective ATPase inhibitor of SMARCA2, with the first patient dosed in October 2024.